Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 3/2011

01-03-2011 | Original Research Article

Effect of Memantine on Resting State Default Mode Network Activity in Alzheimer’s Disease

Authors: Mr Marco Lorenzi, Alberto Beltramello, Nicola B. Mercuri, Elisa Canu, Giada Zoccatelli, Francesca B. Pizzini, Franco Alessandrini, Maria Cotelli, Sandra Rosini, Daniela Costardi, Carlo Caltagirone, Giovanni B. Frisoni

Published in: Drugs & Aging | Issue 3/2011

Login to get access

Abstract

Background

Memantine is an approved symptomatic treatment for moderate to severe Alzheimer’s disease that reduces the excitotoxic effects of hyperactive glutamatergic transmission. However, the exact mechanism of the effect of memantine in Alzheimer’s disease patients is poorly understood. Importantly, the default mode network (DMN), which plays a key role in attention, is hypoactive in Alzheimer’s disease and is under glutamatergic control.

Objective

To assess the effect of memantine on the activity of the DMN in moderate to severe Alzheimer’s disease.

Methods

Functional magnetic resonance imaging (MRI) data from 15 patients with moderate to severe Alzheimer’s disease, seven treated with memantine (mean±SD age 77±8 years, mean±SD Mini-Mental State Examination [MMSE] score 16±5) and eight with placebo (mean±SD age 76±6 years, mean±SD MMSE score 13±1), were acquired at baseline (T0) and after 6 months of treatment (T6). Resting state components were extracted after spatial normalization in individual patients with independent component analysis. The consistency of the components was assessed using ICASSO and the DMN was recognized through spatial correlation with a pre-defined template. Voxel-based statistical analyses were performed to study the change in DMN activity from T0 to T6 in the two groups.

Results

At T0, the two groups showed similar DMN activity except in the precuneus and cuneus, where the patients who started treatment with memantine had slightly greater activity (p <0.05 corrected for familywise error [FWE]). The prospective comparison between T0 and T6 in the treated patients showed increased DMN activation mapping in the precuneus (p <0.05, FWE corrected), while the prospective comparison in the untreated patients did not show significant changes. The treatment×time interaction term was significant at p <0.05, FWE corrected.

Conclusions

The results suggest a positive effect of memantine treatment in patients with moderate to severe Alzheimer’s disease, resulting in an increased resting DMN activity in the precuneus region over 6 months. Future studies confirming the present findings are required to further demonstrate the beneficial effects of memantine on the DMN in Alzheimer’s disease.
Appendix
Available only for authorised users
Literature
1.
Areosa SA, Sherriff F. Memantine for dementia. Cochrane Database Syst Rev 2005; (3): CD003154
2.
Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80(6): 600–7PubMedCrossRef
3.
Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006; 14(8): 704–5PubMedCrossRef
4.
Tariot PN, Farlow MR, Grossberg GT. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291(3): 317–24PubMedCrossRef
5.
Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2008; 13(1): 97–107PubMed
6.
Schmidt R, Ropele S, Pendl B, et al. Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. J Neurol Neurosurg Psychiatry 2008; 79(12): 1312–17PubMedCrossRef
7.
Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system — too little activation is bad, too much is even worse. Neuropharmacology 2007; 53(6): 699–723PubMedCrossRef
8.
Seeman P, Caruso C, Lasaga M. Memantine agonist action at dopamine D2High receptors. Synapse 2008; 62(2): 149–53PubMedCrossRef
9.
Giustizieri M, Cucchiaroni ML, Guatteo E, et al. Memantine inhibits ATP-dependent K+ conductances in dopamine neurons of the rat substantia nigra pars compacta. J Pharmacol Exp Ther 2007; 322(2): 721–9PubMedCrossRef
10.
Hesse S, Ballaschke O, Barthel H, et al. Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder. Psychiatry Res 2009; 171(2): 120–8PubMedCrossRef
11.
Gilden DL, Marusich LR. Contraction of time in attention-deficit hyperactivity disorder. Neuropsychology 2009; 23(2): 265–9PubMedCrossRef
12.
Monastero R, Camarda C, Pipia C, et al. Visual hallucinations and agitation in Alzheimer’s disease due to memantine: report of three cases. J Neurol Neurosurg Psychiatry 2007; 78(5): 546PubMedCrossRef
13.
Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci 2007; 8(9): 700–11PubMedCrossRef
14.
Fransson P. How default is the default mode of brain function? Further evidence from intrinsic BOLD signal fluctuations. Neuropsychologia 2006; 44(14): 2836–45PubMedCrossRef
15.
Gusnard DA, Akbudak E, Shulman GL, et al. Medial prefrontal cortex and self-referential mental activity: relation to a default mode of brain function. Proc Natl Acad Sci U S A 2001; 98: 4259–64PubMedCrossRef
16.
Broyd SJ, Demanuele C, Debener S, et al. Default-mode brain dysfunction in mental disorders: a systematic review. Neurosci Biobehav Rev 2009; 33(3): 279–96PubMedCrossRef
17.
Rombouts S, Barkhof F, Goekoop R, et al. Altered resting state networks in mild cognitive impairment and mild Alzheimer’s. Hum Brain Mapp 2005; 26: 231–9PubMedCrossRef
18.
Liu Y, Wang K, Yu C, et al. Regional homogeneity, functional connectivity and imaging markers of Alzheimer’s disease: a review of resting-state fMRI studies. Neuropsychologia 2008; 46(6): 1648–56PubMedCrossRef
19.
Greicius MD, Srivastava G, Reiss AL, et al. Default-mode network activity distinguishes Alzheimer’s disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A 2004; 101: 4637–42PubMedCrossRef
20.
Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25: 7709–17PubMedCrossRef
21.
Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357(9263): 1191–4PubMedCrossRef
22.
Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134(8): 663–94PubMed
23.
McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34(7): 939–44PubMedCrossRef
24.
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412–4PubMedCrossRef
25.
Rosen WG, Terry RD, Fuld PA, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980; 7(5): 486–8PubMedCrossRef
26.
27.
Lezak MD, Howieson DB, Loring DW, et al. Neuropsychological assessment. 4th ed. New York (NY): Oxford University Press, 2004
28.
Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3): 189–98PubMedCrossRef
29.
Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44(12): 2308–14PubMedCrossRef
30.
Eshed I, Althoff CE, Hamm B, et al. Claustrophobia and premature termination of magnetic resonance imaging examinations. J Magn Reson Imaging 2007; 26(2): 401–4PubMedCrossRef
31.
Calhoun VD, Adali T, Pearlson GD, et al. A method for making group inferences from functional MRI data using independent component analysis. Hum Brain Mapp 2001; 14(3): 140–51PubMedCrossRef
32.
Correa N, Adali T, Calhoun VD. Performance of blind source separation algorithms for fMRI analysis using a group ICA method. Magn Reson Imaging 2007; 25(5): 684–94PubMedCrossRef
33.
Maldjian JA, Laurienti PJ, Kraft RA, et al. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003; 19(3): 1233–9PubMedCrossRef
34.
Hoyer S. Age as risk factor for sporadic dementia of the Alzheimer type? Ann N Y Acad Sci 1994 May 31; 719: 248–56PubMedCrossRef
35.
Noda M, Nakanishi H, Akaike N. Glutamate release from microglia via glutamate transporter is enhanced by amyloid-beta peptide. Neuroscience 1999; 92(4): 1465–74PubMedCrossRef
36.
Harris NG, Plant HD, Inglis BA, et al. Neurochemical changes in the cerebral cortex of treated and untreated hydrocephalic rat pups quantified with in vitro 1H-NMR spectroscopy. J Neurochem 1997; 68(1): 305–12PubMedCrossRef
37.
Magistretti PJ, Pellerin L. Astrocytes couple synaptic activity to glucose utilization in the brain. News Physiol Sci 1999 Oct; 14: 177–82PubMed
38.
Wu J, Anwyl R, Rowan MJ. beta-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. Neuroreport 1995; 6(17): 2409–13PubMedCrossRef
39.
Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol 2006; 6(1): 61–7PubMedCrossRef
40.
Gruetter R, Seaquist ER, Kim S, et al. Localized in vivo 13C-NMR of glutamate metabolism in the human brain: initial results at 4 tesla. Dev Neurosci 1998; 20(4–5): 380–8PubMedCrossRef
41.
Shen J, Petersen KF, Behar KL, et al. Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Proc Natl Acad Sci U S A 1999; 96(14): 8235–40PubMedCrossRef
42.
Sibson NR, Dhankhar A, Mason GF, et al. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc Natl Acad Sci U S A 1998; 95(1): 316–21PubMedCrossRef
43.
Aubert A, Pellerin L, Magistretti PJ, et al. A coherent neurobiological framework for functional neuroimaging provided by a model integrating compartmentalized energy metabolism. Proc Natl Acad Sci USA 2007; 104(10): 4188–93PubMedCrossRef
44.
Magistretti PJ, Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci 1999; 354(1387): 1155–63PubMedCrossRef
45.
Lin AP, Shic F, Enriquez C, et al. Reduced glutamate neurotransmission in patients with Alzheimer’s disease: an in vivo (13) C magnetic resonance spectroscopy study. MAGMA 2003; 16(1): 29–42PubMedCrossRef
46.
Parpura-Gill A, Beitz D, Uemura E. The inhibitory effects of beta amyloid on glutamate and glucose uptakes by cultured astrocytes. Brain Res 1997; 754: 65–71PubMedCrossRef
47.
Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997; 42: 85–94PubMedCrossRef
48.
Damoiseaux JS, Keller KE, Menon V, et al. Default mode network connectivity tracks clinical progression in Alzheimer’s disease. San Francisco (CA): Organization for the Human Brain Mapping, 2009
49.
Peters M, Romieu P, Maurice T, et al. Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci 2004; 19(8): 2212–20CrossRef
50.
Meisner F, Scheller C, Kneitz S, et al. Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. Neuropsychopharmacology 2008; 33(9): 2228–36PubMedCrossRef
51.
Achard S, Bullmore E. Efficiency and cost of economical brain functional networks. PLoS Comput Biol 2007; 3(2): e17PubMedCrossRef
52.
Thomas TC, Grandy DK, Gerhardt GA, et al. Decreased dopamine D4 receptor expression increases extracellular glutamate and alters its regulation in mouse striatum. Neuropsychopharmacology 2009; 34(2): 436–45PubMedCrossRef
53.
Konradi C, Leveque JC, Hyman SE. Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. J Neurosci 1996; 16(13): 4231–9PubMed
54.
Keefe KA, Ganguly A. Effects of NMDA receptor antagonists on D1 dopamine receptor-mediated changes in striatal immediate early gene expression: evidence for involvement of pharmacologically distinct NMDA receptors? Dev Neurosci 1998; 20(2–3): 216–8PubMedCrossRef
55.
Northoff G, Walter M, Schulte RF, et al. GABA concentrations in the human anterior cingulate cortex predict negative BOLD responses in fMRI. Nat Neurosci 2007; 10(12): 1515–7PubMedCrossRef
56.
Molinaro G, Battaglia G, Riozzi B, et al. Memantine treatment reduces the expression of the K(+)/CL(−)cotrans-porter KCC2 in the hippocampus and cerebral cortex, and attenuates behavioural responses mediated by GABA(A) receptor activation in mice. Brain Res 2009; 1265: 75–9PubMedCrossRef
57.
Song MS, Rauw G, Baker GB, et al. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. Eur J Neurosci 2008; 28(10): 1989–2002PubMedCrossRef
58.
Frisoni GB, Fox NC, Jack CR, et al. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010 Feb; 6(2): 67–77PubMedCrossRef
59.
Lin Q, Zheng Y, Yin F, et al. A fast algorithm for one-unit ICA-R. Information Sci 2007; 177: 1265–75CrossRef
Metadata
Title
Effect of Memantine on Resting State Default Mode Network Activity in Alzheimer’s Disease
Authors
Mr Marco Lorenzi
Alberto Beltramello
Nicola B. Mercuri
Elisa Canu
Giada Zoccatelli
Francesca B. Pizzini
Franco Alessandrini
Maria Cotelli
Sandra Rosini
Daniela Costardi
Carlo Caltagirone
Giovanni B. Frisoni
Publication date
01-03-2011
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 3/2011
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/11586440-000000000-00000

Other articles of this Issue 3/2011

Drugs & Aging 3/2011 Go to the issue

Original Research Article

Effects of Anticholinergic Drugs on Verbal Episodic Memory Function in the Elderly

Original Research Article

Potentially Inappropriate Medication Use Among Finnish Non-Institutionalized People Aged ≥65 Years

Adis Drug Profile

Naproxen/Esomeprazole Fixed-Dose Combination

Review Article

Use of Low-Molecular-Weight Heparins and New Anticoagulants in Elderly Patients with Renal Impairment

Review Article

Optimal Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia

Original Research Article

Polypharmacy, Aging and Potential Drug-Drug Interactions in Outpatients in Taiwan
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits